| 초록 |
Nitric oxide (NO) has been known to play important roles in the control of tumor progression. Recent researches have shown the potential of NO in combination with chemotherapeutic agents to enhance its cytotoxicity for a variety of cancers. However, the direct delivery of NO into tumor cells is problematic, because NO has an extremely short half-life in the body. Herein, we developed NO-generating hyaluronic acid nanoparticles (GSNO-HANPs) using the S-nitrosoglutathione (GSNO) as an endogenous NO donor. NO of GSNO-HANPs had long half-life than NO of GSNO. Because nanoparticles shielded GSNO from external response. The GSNO-HANPs in an extracellular environment (pH 7.4, ascorbic acid = 80 μM) showed a retarded release pattern of NO. In contrast, the GSNO-HANPs demonstrated the much faster NO release at an intracellular environment (pH 5.0, ascorbic acid = 5 mM). We verified in vitro therapeutic efficacy using the GSNO-HANPs as an adjuvant for anticancer activity of doxorubicin (DOX). |
